Skip to content

About Avicanna


Avicanna Is a Commercial-Stage International Biopharmaceutical Company Focused on the Advancement and Commercialization of Evidence-Based Cannabinoid-Based Products for the Global Medical and Pharmaceutical Market Segments
Avicanna is a commercial and scale-up stage biopharmaceutical company established in R&D, and commercialization of evidence-based cannabinoid products for the international consumer, medical and pharmaceutical market segments. Supported by its Canadian scientific platform, Avicanna has successfully commercialized its proprietary products into 19 international markets.

Market Segments

Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products

Four Commercial Stage Business Pillars

Avicanna’s scientific platform has resulted in 30+ commercial and proprietary formulations and products
Including medical cannabis, medical cannabis care, Pharmaceutical products and active pharmaceutical ingredients

Medical Cannabis Care Platform

Medical Cannabis Products

Pharmaceutical Products

Active Pharmaceutical Ingredients


Medical Cannabis & Wellness Products

Medical Cannabis Products and RHO Phyto

The portfolio contains a diverse range of formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids such as cannabidiol (“CBD”), cannabigerol (“CBG”), and tetrahydrocannabinol (“THC”) for international medical and wellness market segments 

The formulary is supported by ongoing consumer, patient, and medical community education and training including

The brand is currently available nationwide to patients in medical channels across Canada including launched August 2023. It is also accessible through several other medical institutions including The University Health Network (“UHN”) and the Odette Cancer Centre pharmacy of Sunnybrook Health Science Centre, a major hospital group in Canada. The products are also found in Canadian adult-use sales channels through provincial retailers in five provinces including Ontario, Alberta, British Columbia, New Brunswick, Manitoba, and Saskatchewan.


Pharmaceutical Preparation and Pipeline of Proprietary Drug Candidates

Pharmaceutical candidates designed to address 5 major clinical indications

Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of indication-specific drug candidates that are in various stages of clinical development, registration, and commercialization.

These cannabinoid-based drug candidates are designed to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.

3 Medical Cannabis Care Platform is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the patient journey. is operated by Northern Green Canada Inc. under an agreement and features diverse portfolio of products and a pharmacist led patient support groups such as veterans and collaborating with public and private providers for adjudication and reimbursement and educational resources to facilitate the incorporation of medical cannabis into health care regimes.


Active Pharmaceutical Ingredients (Aureus Santa Marta™)

Aureus Santa Marta is a raw materials that provides Avicanna’s low cost and consistent supply of cannabinoids for its finished products through in-house cultivation and extraction. Providing the pharmaceutical partners with active pharmaceutical ingredients (API) with completed exports into 17 international markets.

Scientific Platform

R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products

Scientific Platform

Setting the Standard in the cannabinoid industry with advanced and evidence based products 

R&D headquarters in Toronto, Canada with drug development pipeline including sustained release tablets, transdermal patches and nano particle formulations.


Proprietary Commercial Products




Canadian Government Research Grants Awarded Since 2020


Pending Patents


Health Canada Cannabis
Research Licenses
to Avicanna
or Institutional Collaborators